SecBot SecBot
8-K ·Filed Jul 23, 2026

ATRC

AtriCure, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed3mo ago SEC0001323885-26-000032
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

Monitor the BoxX-NoAF and LeAAPS clinical trial readouts as additional catalysts. The raised guidance supports a positive longer-term view.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$35.04
T+0 close · Jul 23, 2026 · via day close
Latest settled
+58.48%
T+60 · $55.53
Vs SPY
+55.18%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 24 $35.04entry
  2. T+1 · 4mo ago +6.65%α +6.63% · $37.37
  3. T+5 · 4mo ago +14.58%α +14.21% · $40.15
  4. T+20 · 3mo ago +39.78%α +36.16% · $48.98
  5. T+60 · 29d ago +58.48%α +55.18% · $55.53
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AtriCure reported Q2 2026 results with a massive EPS beat of $0.18 vs $0.03 consensus (+500%), revenue of $153.6M (+12.8% YoY) and a swing to net income of $9.0M from a loss last year. The company raised full-year revenue guidance to $602M-$610M and adjusted EBITDA guidance to $85M-$89M, signaling accelerating profitability.

Key Financial Metrics

EPS
$0.18
est $0.03 · +500.0%
Revenue
$153.6M
+12.8% YoY
Rating
strong beat
Guidance
$602 million to $610 million
raised
Gross Margin
77.2%

Key Facts

  • Q2 2026 revenue $153.6M, +12.8% YoY (12.4% constant currency)
  • GAAP EPS $0.18 vs $0.03 consensus (500% beat)
  • Net income $9.0M vs loss of $6.2M in Q2 2025
  • Gross margin 77.2%, +269 bps YoY
  • Adjusted EBITDA $27.3M, +78% YoY
  • Full-year 2026 revenue guidance raised to $602M-$610M (from $600M-$610M)
  • Full-year adjusted EBITDA guidance raised to $85M-$89M (from $80M-$82M)
  • Full-year adjusted EPS guidance initiated at $0.24-$0.32
  • Cash generation of $21.6M in Q2

Financial Impact

EPS beat by 500% ($0.18 vs $0.03), revenue growth 12.8% YoY, guidance raised across all metrics

revenueepsnet incomeadjusted EBITDA

Risk Factors

  • Clinical trial data readouts (BoxX-NoAF, LeAAPS) are binary and could reverse sentiment
  • Competition from catheter-based technologies and drugs
  • Reliance on FDA approvals and reimbursement for new products
  • Elevated share-based compensation ($12.3M in Q2) dilutes earnings

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
81% bullish (16 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001323885-26-000032
Document: atrc-20260723.htm0001323885-26-000032
Document: 0001323885-26-000032-index-headers.html0001323885-26-000032
Document: 0001323885-26-000032-index.html0001323885-26-000032
Document: 0001323885-26-000032.txt0001323885-26-000032
8-K Data (Synthetic)0001323885-26-000032

US Market Status

Market Closed · Opens in 7h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 23, 2026